Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Verta is a ginger-based dietary supplement developed by Omnifarma Kiev, containing a standardized extract of *Zingiber officinale*. It is primarily utilized to support joint health, improve mobility, and alleviate pain associated with inflammatory conditions such as osteoarthritis. The therapeutic effects are attributed to active constituents like gingerols and shogaols, which inhibit the enzymes cyclooxygenase (COX) and lipoxygenase (LOX). By blocking these pathways, Verta reduces the production of pro-inflammatory prostaglandins and leukotrienes, thereby exerting anti-inflammatory and analgesic properties. It is marketed as a natural alternative or adjunct to conventional non-steroidal anti-inflammatory drugs (NSAIDs).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Verta.